Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GKOS GLAUKOS Corp
- Stocks
- Healthcare
- NYSE: GKOS
Price (delayed)
$89.96
Market cap
$5.14B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$5.13B
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery,
Highlights
GLAUKOS's equity has surged by 69% YoY
The revenue has grown by 24% YoY and by 5% from the previous quarter
The debt has shrunk by 72% YoY but it has increased by 2% QoQ
Key stats
What are the main financial stats of GKOS
Market
Valuations
Earnings
Shares outstanding
57.14M
Market cap
$5.14B
Enterprise value
$5.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.66
Price to sales (P/S)
12.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.67
Revenue
$404.52M
Gross profit
$306.44M
Operating income
-$103.98M
Net income
-$123.68M
EBIT
-$115.21M
EBITDA
-$75.96M
Free cash flow
-$53.2M
Per share
Balance sheet
Liquidity
EPS
-$2.3
EPS diluted
-$2.3
Free cash flow per share
-$0.94
Book value per share
$13.51
Revenue per share
$7.14
TBVPS
$11.34
Total assets
$966.18M
Total liabilities
$202.22M
Debt
$105.48M
Equity
$763.96M
Working capital
$376.02M
Debt to equity
0.14
Current ratio
6.49
Quick ratio
5.47
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-18.8%
Gross margin
75.8%
Net margin
-30.6%
Operating margin
-25.7%
Return on assets
-13.1%
Return on equity
-17.3%
Return on invested capital
-20.7%
Return on capital employed
-12.8%
Return on sales
-28.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GKOS stock price
How has the GLAUKOS stock price performed over time
Intraday
-0.64%
1 week
2.68%
1 month
-3.84%
1 year
-16.41%
YTD
-40%
QTD
-8.6%
Financial performance
How have GLAUKOS's revenue and profit performed over time
Revenue
$404.52M
Gross profit
$306.44M
Operating income
-$103.98M
Net income
-$123.68M
Gross margin
75.8%
Net margin
-30.6%
The company's operating margin rose by 38% YoY and by 19% QoQ
The net margin has increased by 29% YoY and by 20% QoQ
The revenue has grown by 24% YoY and by 5% from the previous quarter
The company's gross profit rose by 23% YoY and by 6% QoQ
Price vs fundamentals
How does GKOS's price correlate with its fundamentals
Growth
What is GLAUKOS's growth rate over time
Valuation
What is GLAUKOS stock price valuation
P/E
N/A
P/B
6.66
P/S
12.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.67
GLAUKOS's EPS has increased by 20% YoY and by 17% from the previous quarter
GLAUKOS's equity has surged by 69% YoY
The price to book (P/B) is 29% less than the last 4 quarters average of 9.4 but 7% more than the 5-year quarterly average of 6.2
The P/S is 30% lower than the last 4 quarters average of 18.0 but 4.1% higher than the 5-year quarterly average of 12.1
The revenue has grown by 24% YoY and by 5% from the previous quarter
Efficiency
How efficient is GLAUKOS business performance
The ROE has grown by 42% YoY and by 24% from the previous quarter
The ROIC is down by 34% year-on-year but it is up by 4.2% since the previous quarter
GLAUKOS's ROS has increased by 26% YoY and by 19% from the previous quarter
The return on assets is up by 16% since the previous quarter and by 12% year-on-year
Dividends
What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GKOS.
Financial health
How did GLAUKOS financials performed over time
The company's total liabilities has shrunk by 58% YoY and by 2.7% QoQ
The quick ratio has grown by 22% YoY and by 7% from the previous quarter
The debt is 86% lower than the equity
The debt to equity has plunged by 84% YoY but it has grown by 8% from the previous quarter
The debt has shrunk by 72% YoY but it has increased by 2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.